BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 22521999)

  • 1. Methyl and ethyl ketone analogs of salicylaldehyde isonicotinoyl hydrazone: novel iron chelators with selective antiproliferative action.
    Macková E; Hrušková K; Bendová P; Vávrová A; Jansová H; Hašková P; Kovaříková P; Vávrová K; Simůnek T
    Chem Biol Interact; 2012 May; 197(2-3):69-79. PubMed ID: 22521999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and initial in vitro evaluations of novel antioxidant aroylhydrazone iron chelators with increased stability against plasma hydrolysis.
    Hruskova K; Kovarikova P; Bendova P; Haskova P; Mackova E; Stariat J; Vavrova A; Vavrova K; Simunek T
    Chem Res Toxicol; 2011 Mar; 24(3):290-302. PubMed ID: 21214215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationships of novel salicylaldehyde isonicotinoyl hydrazone (SIH) analogs: iron chelation, anti-oxidant and cytotoxic properties.
    Potůčková E; Hrušková K; Bureš J; Kovaříková P; Špirková IA; Pravdíková K; Kolbabová L; Hergeselová T; Hašková P; Jansová H; Macháček M; Jirkovská A; Richardson V; Lane DJ; Kalinowski DS; Richardson DR; Vávrová K; Šimůnek T
    PLoS One; 2014; 9(11):e112059. PubMed ID: 25393531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aroylhydrazone iron chelators: Tuning antioxidant and antiproliferative properties by hydrazide modifications.
    Hrušková K; Potůčková E; Hergeselová T; Liptáková L; Hašková P; Mingas P; Kovaříková P; Šimůnek T; Vávrová K
    Eur J Med Chem; 2016 Sep; 120():97-110. PubMed ID: 27187862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Activity Relationships of Nitro-Substituted Aroylhydrazone Iron Chelators with Antioxidant and Antiproliferative Activities.
    Hrušková K; Potůčková E; Opálka L; Hergeselová T; Hašková P; Kovaříková P; Šimůnek T; Vávrová K
    Chem Res Toxicol; 2018 Jun; 31(6):435-446. PubMed ID: 29766723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SIH--a novel lipophilic iron chelator--protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death.
    Simůnek T; Boer C; Bouwman RA; Vlasblom R; Versteilen AM; Sterba M; Gersl V; Hrdina R; Ponka P; de Lange JJ; Paulus WJ; Musters RJ
    J Mol Cell Cardiol; 2005 Aug; 39(2):345-54. PubMed ID: 15978614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone.
    Richardson DR; Milnes K
    Blood; 1997 Apr; 89(8):3025-38. PubMed ID: 9108424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron chelation with salicylaldehyde isonicotinoyl hydrazone protects against catecholamine autoxidation and cardiotoxicity.
    Hašková P; Kovaříková P; Koubková L; Vávrová A; Macková E; Simůnek T
    Free Radic Biol Med; 2011 Feb; 50(4):537-49. PubMed ID: 21147217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series.
    Kalinowski DS; Sharpe PC; Bernhardt PV; Richardson DR
    J Med Chem; 2008 Jan; 51(2):331-44. PubMed ID: 18159922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
    Chaston TB; Lovejoy DB; Watts RN; Richardson DR
    Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2,6-Dihydroxybenzaldehyde Analogues of the Iron Chelator Salicylaldehyde Isonicotinoyl Hydrazone: Increased Hydrolytic Stability and Cytoprotective Activity against Oxidative Stress.
    Jansová H; Kubeš J; Reimerová P; Štěrbová-Kovaříková P; Roh J; Šimůnek T
    Chem Res Toxicol; 2018 Nov; 31(11):1151-1163. PubMed ID: 30395451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: a study of salicylaldehyde isonicotinoyl hydrazone (SIH).
    Sterba M; Popelová O; Simůnek T; Mazurová Y; Potácová A; Adamcová M; Guncová I; Kaiserová H; Palicka V; Ponka P; Gersl V
    Toxicology; 2007 Jun; 235(3):150-66. PubMed ID: 17459556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents.
    Becker EM; Lovejoy DB; Greer JM; Watts R; Richardson DR
    Br J Pharmacol; 2003 Mar; 138(5):819-30. PubMed ID: 12642383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prooxidant and antioxidant properties of salicylaldehyde isonicotinoyl hydrazone iron chelators in HepG2 cells.
    Caro AA; Commissariat A; Dunn C; Kim H; García SL; Smith A; Strang H; Stuppy J; Desrochers LP; Goodwin TE
    Biochim Biophys Acta; 2015 Nov; 1850(11):2256-64. PubMed ID: 26275495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and characterization of new iron chelators with anti-proliferative activity: structure-activity relationships of novel thiohydrazone analogues.
    Kalinowski DS; Sharpe PC; Bernhardt PV; Richardson DR
    J Med Chem; 2007 Nov; 50(24):6212-25. PubMed ID: 17963372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products.
    Jansová H; Bureš J; Macháček M; Hašková P; Jirkovská A; Roh J; Wang Q; Franz KJ; Kovaříková P; Šimůnek T
    Toxicology; 2016 Mar; 350-352():15-24. PubMed ID: 27046792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variable inhibitory effects on the formation of dinitrosyl iron complexes by deferoxamine and salicylaldehyde isonicotinoyl hydrazone in K562 cells.
    Meczynska S; Lewandowska H; Sochanowicz B; Sadlo J; Kruszewski M
    Hemoglobin; 2008; 32(1-2):157-63. PubMed ID: 18274993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative analysis of the anti-proliferative activity of combinations of selected iron-chelating agents and clinically used anti-neoplastic drugs.
    Potuckova E; Jansova H; Machacek M; Vavrova A; Haskova P; Tichotova L; Richardson V; Kalinowski DS; Richardson DR; Simunek T
    PLoS One; 2014; 9(2):e88754. PubMed ID: 24586383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron chelators: correlation between effects on Plasmodium spp. and immune functions.
    Golenser J; Domb A; Mordechai-Daniel T; Leshem B; Luty A; Kremsner P
    J Parasitol; 2006 Feb; 92(1):170-7. PubMed ID: 16629332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intralysosomal iron chelation protects against oxidative stress-induced cellular damage.
    Kurz T; Gustafsson B; Brunk UT
    FEBS J; 2006 Jul; 273(13):3106-17. PubMed ID: 16762036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.